Millions of people in the U.S. and around the world are living with hepatitis C virus (HCV). But over the past decade, direct-acting antivirals (DAA) have proven effective against HCV, curing more ...

Hepatitis C infection. Computer illustration showing liver and close-up view of hepatitis C viruses. Studies show that mortality, morbidity, and hepatic decompensation risks increase with coinfection ...

Hepatitis C is the leading cause of chronic liver disease and liver cancer in the world and affects an estimated 51 million people globally. Though the viral infection is easily diagnosable and ...

The FDA expanded the approval of the direct-acting antiviral (DAA) glecaprevir/pibrentasvir (Mavyret), making it the first treatment for acute hepatitis C virus ...

Hepatitis C is a tiny virus with a significant impact. It's a small RNA virus that spreads through the blood and infects the liver. Even though today's medicines can cure it, hepatitis C remains a ...

Please provide your email address to receive an email when new articles are posted on . The approval allows for immediate treatment following diagnosis. Patients treated in a phase 3 study experienced ...

This article estimates the comprehensive value of direct-acting antivirals for the treatment of hepatitis C virus using a generalized cost-effectiveness analysis. Objectives: To estimate the ...

While liver inflammation is the primary area of concern with a hepatitis C virus infection, the condition can also increase your risk of developing kidney-related complications, such as acute kidney ...

Please provide your email address to receive an email when new articles are posted on . May is Hepatitis Awareness Month, and the CDC and its public health partners are raising awareness and ...